Gurgaon, India
Genes2Me, founded in 2016, stands at the forefront of India's Biotechnology arena, focusing on innovative In-Vitro Diagnostics (IVD) solutions tailored for Genomics. With its headquarters in India, the company operates at the intersection of Health Care and Health and Wellness, primarily in manufacturing high-quality, cutting-edge diagnostic tools.
The company is renowned for its comprehensive range of diagnostic offerings, including NGS clinical panels, molecular point-of-care testing solutions, and critical testing kits like RT-PCR and rapid antigen/antibody testing kits. Its product line, featuring brands such as CliSeq, PanCan, and Rapi-Q, is noted for innovation, particularly the Rapi-Q and Rapi-X series, which arguably redefine molecular point-of-care testing globally.
While no recent investment is reported, the potential for investors lies in the firm's technological prowess and strategic position in the global diagnostics market. Genes2Me's continuous expansion into genetic testing across various medical conditions, including oncology and rare diseases, poises it as a promising entity for prospective investors seeking to capitalize on the ever-growing genomics sector.
